(NASDAQ: OKUR) Onkure Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.69%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 62.75%.
Onkure Therapeutics's earnings in 2026 is -$58,705,000.On average, 6 Wall Street analysts forecast OKUR's earnings for 2026 to be -$75,590,410, with the lowest OKUR earnings forecast at -$95,247,319, and the highest OKUR earnings forecast at -$62,506,053. On average, 5 Wall Street analysts forecast OKUR's earnings for 2027 to be -$63,060,852, with the lowest OKUR earnings forecast at -$82,547,676, and the highest OKUR earnings forecast at -$48,899,293.
In 2028, OKUR is forecast to generate -$68,430,663 in earnings, with the lowest earnings forecast at -$92,072,408 and the highest earnings forecast at -$45,072,392.